SCHEMBL117930

SCHEMBL117930

Cc1cc(S(=O)(=O)NCc2ccccc2)ccc1Br

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.65
CYP1A2 P05177 2/20 0.63
CA12 O43570 2/20 0.63
CA9 Q16790 2/20 0.63
CYP3A4 P08684 1/20 0.63
ATM Q13315 1/20 0.63
L3MBTL1 Q9Y468 1/20 0.63
CYP2C19 P33261 1/20 0.59
KEAP1 Q14145 1/20 0.58
POLB P06746 2/20 0.57
LMNA P02545 1/20 0.57
SLC12A2 P55011 1/20 0.57
SLC12A5 Q9H2X9 1/20 0.57
NPC1 O15118 1/20 0.56
RAB9A P51151 1/20 0.56
ALDH1A1 P00352 4/20 0.55
SMN1; SMN2 Q16637 1/20 0.54
CYP19A1 P11511 2/20 0.54
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2499052 0.88 PKM (0.69) PKMCYP1A2CA12CA9CYP3A4
SCHEMBL19400889 0.86 NPC1 (0.73) PKMCYP1A2CA12CA9CYP3A4
SCHEMBL849033 0.84 PKM (0.71) PKMCYP2C19POLBALDH1A1SMN1; SMN2
SCHEMBL120400 0.82 PKM (0.61) PKMCYP1A2CA12CA9CYP3A4
SCHEMBL120482 0.82 LMNA (0.69) PKMCYP1A2CA12CA9CYP3A4
SCHEMBL19197973 0.82 SMN1; SMN2 (0.69) PKMCYP1A2CA12CA9CYP3A4
SCHEMBL16492321 0.80 ALDH1A1 (0.65) CA9NPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL24254522 0.79 CA12 (0.63) PKMCYP1A2CA12CA9CYP3A4
SCHEMBL31113705 0.79 PKM (0.65) PKMCYP1A2CA12CA9CYP3A4
SCHEMBL28836851 0.79 PKM (0.65) PKMCYP1A2CA12CA9CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102427810-A Sulfamoylbenzoic acid derivatives as TRPM8 antagonists RAQUALIA PHARMA INC 2012-04-25 CN disclosed
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-19 US disclosed
EP-2424517-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RaQualia Pharma Inc (JP) 2012-03-07 EP disclosed
WO-2010125831-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS TRPM8, TRPM5, TRPM6 PKM 1399/4885CYP1A2 2926/4885CA12 1502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.